Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
High THC cannabis is an investigational whole-plant botanical product being developed by the Multidisciplinary Association for Psychedelic Studies (MAPS) for the treatment of chronic, treatment-resistant posttraumatic stress disorder (PTSD) in military veterans. The product consists of smoked cannabis containing approximately 12% tetrahydrocannabinol (THC) and less than 0.05% cannabidiol (CBD). Sourced from the National Institute on Drug Abuse (NIDA), it acts as an agonist at cannabinoid receptors (CB1 and CB2) within the endocannabinoid system. This intervention was evaluated in the Phase 2 MJP1 trial, a randomized, triple-blind, placebo-controlled crossover study designed to assess the safety and efficacy of different cannabis potencies in reducing PTSD symptom severity as measured by the CAPS-5 scale.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on high THC cannabis.